Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
CPRX's Cash to Debt is ranked higher than
97% of the 789 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. CPRX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CPRX' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Interest Coverage No Debt
CPRX's Interest Coverage is ranked higher than
97% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 104.15 vs. CPRX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CPRX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 19.19
M-Score: -3.37
WACC vs ROIC
17.37%
-2784.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -38.54
CPRX's ROE (%) is ranked lower than
85% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.55 vs. CPRX: -38.54 )
Ranked among companies with meaningful ROE (%) only.
CPRX' s ROE (%) Range Over the Past 10 Years
Min: -137.75  Med: -57.88 Max: -22.89
Current: -38.54
-137.75
-22.89
ROA (%) -36.18
CPRX's ROA (%) is ranked lower than
86% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. CPRX: -36.18 )
Ranked among companies with meaningful ROA (%) only.
CPRX' s ROA (%) Range Over the Past 10 Years
Min: -105.81  Med: -51.22 Max: -22.19
Current: -36.18
-105.81
-22.19
ROC (Joel Greenblatt) (%) -1205.86
CPRX's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.88 vs. CPRX: -1205.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CPRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -24183.33  Med: -7935.11 Max: -915.32
Current: -1205.86
-24183.33
-915.32
EBITDA Growth (3Y)(%) 13.40
CPRX's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.60 vs. CPRX: 13.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CPRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.7  Med: 5.1 Max: 51.2
Current: 13.4
-30.7
51.2
EPS Growth (3Y)(%) 21.30
CPRX's EPS Growth (3Y)(%) is ranked higher than
72% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. CPRX: 21.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CPRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -33.7  Med: 8.6 Max: 48.9
Current: 21.3
-33.7
48.9
» CPRX's 10-Y Financials

Financials (Next Earnings Date: 2017-03-16)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

CPRX Guru Trades in Q4 2015

Steven Cohen 2,276,923 sh (+3.20%)
» More
Q1 2016

CPRX Guru Trades in Q1 2016

Jim Simons 175,800 sh (New)
Steven Cohen 2,263,576 sh (-0.59%)
» More
Q2 2016

CPRX Guru Trades in Q2 2016

Steven Cohen 2,366,964 sh (+4.57%)
Jim Simons Sold Out
» More
Q3 2016

CPRX Guru Trades in Q3 2016

Jim Simons 15,000 sh (New)
Steven Cohen 2,366,964 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CPRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:MSLI, NAS:CPIX, NAS:SCYX, NAS:SPHS, NAS:ARDM, NAS:CPHR, NAS:STDY, NAS:NEOS, NAS:BPTH, NAS:LPCN, NAS:ADMP, NAS:PSDV, OTCPK:ELTP, NAS:JNP, NAS:MEIP, NAS:SMMT, NAS:EPIX, NAS:ZYNE, OTCPK:NRIFF, OTCPK:MRPHF » details
Traded in other countries:CN2.Germany,
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The Company is engaged in the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders.

Catalyst Pharmaceuticals Inc was incorporated in Delaware in July 2006. The Company is a biopharmaceutical company. The Company is engaged in developing and commercializing therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette syndrome. Catalyst's candidate, Firdapse for the treatment of LEMS, recently completed testing in a global, multi-center, pivotal Phase 3 trial resulting in positive top-line data. Firdapse for the treatment of LEMS has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and orphan drug designation for CMS. Firdapse is the first and only European approved drug for symptomatic treatment in adults with LEMS. The Company is also enagaged in developing CPP-115 to treat infantile spasms, epilepsy and other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette syndrome. It has three pharmaceutical products in development namely Firdapse(tm), CPP-115 and CPP-109. The Company also competes against biotechnology companies, universities, government agencies, and other research institutions in the development of substance abuse treatments, technologies and processes. The pharmaceutical industry is intensely competitive, and any product candidate developed or licensed by the Company would likely compete with existing drugs and therapies. In the United States, drugs are subject to rigorous regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations, as well as other federal and state statutes.

Ratios

vs
industry
vs
history
P/B 2.26
CPRX's P/B is ranked higher than
61% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. CPRX: 2.26 )
Ranked among companies with meaningful P/B only.
CPRX' s P/B Range Over the Past 10 Years
Min: 2.12  Med: 7.43 Max: 29.61
Current: 2.26
2.12
29.61
Current Ratio 22.57
CPRX's Current Ratio is ranked higher than
97% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. CPRX: 22.57 )
Ranked among companies with meaningful Current Ratio only.
CPRX' s Current Ratio Range Over the Past 10 Years
Min: 0.75  Med: 13.28 Max: 54.56
Current: 22.57
0.75
54.56
Quick Ratio 22.57
CPRX's Quick Ratio is ranked higher than
97% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. CPRX: 22.57 )
Ranked among companies with meaningful Quick Ratio only.
CPRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 13.28 Max: 54.56
Current: 22.57
0.75
54.56

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -26.00
CPRX's 3-Year Average Share Buyback Ratio is ranked lower than
84% of the 435 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.60 vs. CPRX: -26.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CPRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -74.4  Med: -31.6 Max: -12.9
Current: -26
-74.4
-12.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.28
CPRX's Price/Net Cash is ranked higher than
92% of the 210 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.40 vs. CPRX: 2.28 )
Ranked among companies with meaningful Price/Net Cash only.
CPRX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.38  Med: 3.55 Max: 18.63
Current: 2.28
1.38
18.63
Price/Net Current Asset Value 2.24
CPRX's Price/Net Current Asset Value is ranked higher than
88% of the 468 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.66 vs. CPRX: 2.24 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CPRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.26  Med: 3.4 Max: 10.09
Current: 2.24
1.26
10.09
Price/Tangible Book 2.19
CPRX's Price/Tangible Book is ranked higher than
68% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. CPRX: 2.19 )
Ranked among companies with meaningful Price/Tangible Book only.
CPRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.25  Med: 3.37 Max: 10.09
Current: 2.19
1.25
10.09
Earnings Yield (Greenblatt) (%) -39.90
CPRX's Earnings Yield (Greenblatt) (%) is ranked lower than
94% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. CPRX: -39.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CPRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -100000.2  Med: 0 Max: 2924.23
Current: -39.9
-100000.2
2924.23

More Statistics

EPS (TTM) $ -0.25
Beta2.00
Short Percentage of Float3.83%
52-Week Range $0.51 - 3.00
Shares Outstanding (Mil)82.87

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 18 68
EPS ($) -0.25 -0.26 -0.11 0.16
EPS w/o NRI ($) -0.25 -0.26 -0.11 0.16
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CPRX

Headlines

Articles On GuruFocus.com
Catalyst Pharmaceuticals Insider Picks Up Shares of Company Oct 05 2015 
Piper Jaffray Remains Bullish on Catalyst Pharmaceuticals Following the Close of its Recent Public O Feb 17 2015 
Weekly CEO Buys Highlight: BH, CLMS, OPK, GPC, CPRX Jan 18 2015 
Weekly CEO Buys Highlight: BH, CLMS, OPK, CPRX, BRT Jan 12 2015 
Largest Insider Buys of the Week Oct 25 2013 
Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD Jul 09 2012 
Weekly CFO Buys Highlight: EMC, DVOX, NANX, CPRX, CCRN Jun 04 2012 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Nov 15 2010 
Catalyst Pharmaceutical Partners Inc. Reports Operating Results (10-Q) Aug 12 2010 
Catalyst Pharmaceutical Partners Inc. (CPRX) CEO Patrick J Mcenany buys 9,359 Shares Jun 16 2010 

More From Other Websites
Catalyst Pharmaceuticals, Inc. :CPRX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1,... Dec 01 2016
Catalyst Pharmaceuticals to Participate in the 28th Annual Piper Jaffray Healthcare Conference Nov 21 2016
CATALYST PHARMACEUTICALS, INC. Financials Nov 17 2016
Alexion (ALXN) Offers Long-Term Phase III Data on Kanuma Nov 14 2016
Catalyst reports 3Q loss Nov 09 2016
Catalyst reports 3Q loss Nov 09 2016
CATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 09 2016
Catalyst Pharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate... Nov 09 2016
Catalyst Pharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate... Nov 09 2016
CATALYST PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 09 2016
Q3 2016 Catalyst Pharmaceuticals Inc Earnings Release - After Market Close Nov 09 2016
Catalyst Pharma (CPRX) Q3 Earnings: Will Stock Surprise? Nov 07 2016
Catalyst Reaches Agreement with FDA (CPRX) Nov 03 2016
Catalyst Pharmaceuticals Inc (CPRX) Isn’t Out Of The Woods With Firdapse Just Yet Nov 01 2016
Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on... Nov 01 2016
Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on... Nov 01 2016
Research Reports Coverage on Generic Drugs Stocks -- Evoke Pharma, Catalyst Pharma, Neurocrine... Oct 31 2016
CATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 31 2016
Catalyst Pharmaceuticals Receives Special Protocol Assessment (SPA) from the FDA for Second Phase 3... Oct 31 2016
Catalyst Pharmaceuticals Receives Special Protocol Assessment (SPA) from the FDA for Second Phase 3... Oct 31 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)